Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in cancer medicine, having contributed to a widening of therapeutic options across oncological indications. Disruption of immune tolerance is the key mechanism of action of checkpoint inhibitors and, whilst immune-related adverse events are a typical class effect of these compounds, the relationship between toxicity and response is not fully understood. Awareness and vigilance are paramount in recognising potentially life-threatening toxicities and managing them in a timely manner. In this review article, we provide an overview of the clinical features, pathologic findings and management principles of common immune-related toxicities, attempting to provide mechanistic insight into an increasingly common complication of cancer therapy.
Date Issued
2020-02
Date Acceptance
2019-10-01
Citation
Immunology, 2020, 159 (2), pp.167-177
ISSN
0019-2805
Publisher
Wiley
Start Page
167
End Page
177
Journal / Book Title
Immunology
Volume
159
Issue
2
Copyright Statement
© 2019 John Wiley & Sons Ltd. This is the accepted version of the following article: Fessas, P. , Possamai, L. A., Clark, J. , Daniels, E. , Gudd, C. , Mullish, B. H., Alexander, J. L. and Pinato, D. J. (2019), Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. Accepted Author Manuscript, which has been published in final form at https://doi.org/10.1111/imm.13141
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/31646612
Grant Number
RDA02
Subjects
immune checkpoint inhibitors
immunotherapy
toxicity
Publication Status
Published online
Coverage Spatial
England
Date Publish Online
2019-10-23